Table 3.
Demographic characteristics and prevalence of comorbidities by allopurinol use in episodes with incident myocardial infarction (MI)
| No MI | MI | P value | ||
|---|---|---|---|---|
| Not on allopurinol | On allopurinol | |||
| Number of episodes | 27,754 | 607 | 937 | |
| Age (years), mean (SD) | 76.5 (7.4) | 77.6 (7.5) | 78.4 (7.6) | 0.046 |
| Gender | 0.13 | |||
| Male | 13,727 (49.5) | 290 (47.8) | 485 (51.8) | |
| Female | 14,027 (50.5) | 317 (52.2) | 452 (48.2) | |
| Race | 0.07 | |||
| White | 21,922 (79.0) | 459 (75.6) | 750 (80.0) | |
| Black | 3374 (12.2) | 97 (16.0) | 112 (12.0) | |
| Others | 2458 (8.8) | 51 (8.4) | 75 (8.0) | |
| Charlson-Romano comorbidity index score, mean (SD) | 3.65 (3.23) | 4.52 (3.32) | 4.96 (3.47) | 0.01 |
| Comorbidity | ||||
| Diabetes | 11076 (39.91) | 290 (47.8) | 482 (51.4) | 0.16 |
| Hypertension | 23456 (84.5) | 544 (89.6) | 811 (89.6) | 0.07 |
| CVD | 3442 (12.4) | 106 (17.5) | 184 (19.6) | 0.28 |
| PVD | 4631 (16.7) | 133 (21.9) | 247 (26.4) | 0.047 |
All numbers are n (%), unless specified otherwise
P value compares episodes with versus without allopurinol in patients who had an MI
Significant differences and p values are in bold
CVD cerebrovascular disease, PVD peripheral vascular disease, SD standard deviation